L. Magnani

Epigenetic heritability of cell plasticity drives cancer drug resistance through one-to-many genotype to phenotype mapping

The paper shows how epigenetic heritability of cell plasticity contributes to cancer drug resistance through a one-to-many genotype-to-phenotype mapping.

Phenotypic plasticity and genetic control in colorectal cancer evolution

This study investigates phenotypic plasticity and genetic control in colorectal cancer by analyzing gene expression and genetic variation across multiple tumor regions.

The co-evolution of the genome and epigenome in colorectal cancer

This study examines the co-evolution of genome and epigenome in colorectal cancer using single-clone spatial multi-omic profiling, revealing epigenetic changes and their impact on mutation accumulation.

Genetic and epigenetic driven variation in regulatory regions activitycontribute to adaptation and evolution under endocrine treatment

This study identifies non-coding DNA alterations in hormone-dependent breast cancer that contribute to endocrine therapy resistance and disease progression.

Systems medicine dissection of chromosome 1q amplification reveals oncogenic regulatory circuits and informs targeted therapy in cancer

This study identifies oncogenic regulatory circuits driven by chromosome 1q amplification in cancer and proposes targeted therapy strategies using a systems medicine approach.

Assessment of the evolutionary consequence of putative driver mutations in colorectal cancer with spatial multiomic data

This study uses spatial multiomic data to assess the evolutionary impact of putative driver mutations in colorectal cancer, identifying both genetic and non-genetic factors influencing subclonal expansion.

Unperturbed dormancy recording reveals stochastic awakening strategies in endocrine treated breast cancer cells

This study investigates dormancy and awakening in endocrine-treated breast cancer cells, revealing stochastic awakening strategies and the role of epigenetic decay.

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

This study identifies VGLL1 as a driver of resistance to endocrine therapy in ER+ breast cancer and shows that targeting VGLL1/TEAD interaction can inhibit resistant cell growth.

Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer

This study identifies ATF3 as a novel mediator of endocrine resistance in breast cancer through time-resolved profiling and validates its role in key signaling pathways and clinical relevance.

Nano-analytical Characterization of Breast Tissue Biopsies Reveals an Association between Spherical Nano and Micro Particles and Invasive Malignant Breast Tumours.

This study identifies magnesium-containing spherical nano and micro particles in invasive breast cancers using nano-analytical methods, showing their concentration increases with cancer progression.

Exploiting evolutionary herding to control drug resistance in cancer

This paper demonstrates evolutionary herding in non-small cell lung cancer to control drug resistance by shifting clonal composition and inducing collateral sensitivity.

Single-cell Transcriptomics reveals multi-step adaptations to endocrine therapy

This study uses single-cell transcriptomics to identify pre-adapted cells that undergo reprogramming to develop resistance to endocrine therapy in breast cancer.

SREBP1 drives KRT80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer

This study identifies SREBP1-driven KRT80 upregulation as a mechanism promoting invasion in endocrine-resistant ERα breast cancer through cytoskeletal changes and increased tumor stiffness.

Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

This study maps enhancers in luminal breast cancer to reveal phenotypic heterogeneity and its evolutionary dynamics during treatment.